Form 4 for AKTX Akari Therapeutics Plc
Accepted 2025-06-12 00:00:00 ET · period of report 2025-06-10 · accession 0000950170-25-085472 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-12 | 2025-06-10 | AKTX | Gaslightwala Abizer | CEO, Dir | A - Grant | $1.27 | +20.0K | 201.4K | +11% | +$25.4K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2025-06-10 | A | A | 20,000 | $1.27 | 201,428 | D | — | — | (F1) Each American Depositary Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. (F2) On June 10, 2025, the Reporting Person acquired 20,000 ADS at an average price of $1.27 per ADS. |